Cardax names new chief clinical and regulatory strategist
29 November 2018 -

Honolulu-based Cardax Inc (OTCQB: CDXI) has named Paresh N Soni, MD, PhD as its new chief clinical and regulatory strategist and as a member of the company's Scientific Advisory Board, it was announced yesterday.

Dr Soni was the former senior vice president and head of development for Amarin Corporation. He will guide clinical and regulatory strategy for Cardax's pharmaceutical platform, interact with the FDA, and advise the company on a full range of development issues. He previously led the development of the Amarin's clinical trial and regulatory strategy for its natural product fish oil drug Vascepa, including its MARINE, ANCHOR, and REDUCE-IT clinical studies.

Cardax CEO David G Watumull said, 'We have long thought that natural products with pleiotropic mechanisms of action can safely address unmet medical needs in chronic disease. Dr Soni's work at Amarin helped to validate this approach and we are delighted to be working with him.'